Articles from Aditxt, Inc.

Aditxt, Inc. (NASDAQADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, is pleased to announce that its Board of Directors has authorized management to explore taking its subsidiary, Pearsanta, Inc. (“Pearsanta”), public via a proposed initial public offering (“IPO”) in 2025. This decision aligns with Aditxt's mission to secure and develop transformative health innovations, positioning them for accelerated growth and broader market impact.

Aditxt, Inc. (NASDAQADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today announced that its subsidiary, Adimune, Inc. (“Adimune”), has successfully completed all preclinical efficacy and safety studies for its antigen-specific gene therapy, ADI-100. This achievement represents a major milestone as Adimune prepares to submit a Clinical Trial Application (CTA)/Investigational New Drug (IND) application to initiate first-in-human clinical trials for ADI-100 in the treatment of Type 1 Diabetes (T1D), Psoriasis, and in collaboration with Mayo Clinic, Stiff-Person Syndrome (SPS).

Aditxt, Inc. (NASDAQADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today provided an update to its shareholders on the utilization of its Equity Line of Credit (“ELOC”) and At-the-Market (“ATM”) facility, as well as its outstanding number of shares.

Aditxt, Inc. (NASDAQADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today shared an important milestone for its target acquisition, Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (“Appili”). Shareholders of Appili overwhelmingly voted in favor of a plan of arrangement for Aditxt to acquire all issued and outstanding Class A common shares of Appili. For additional information and results of Appili’s special meeting of shareholders, please visit this link.

Aditxt, Inc. (NASDAQADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, announced today that its acquisition target, Evofem Biosciences, Inc. (“Evofem”) (OTCQB: EVFM), has secured voting agreements with certain of its investors to ensure they will vote in favor of the merger proposal at Evofem’s upcoming Special Meeting of Stockholders (the “Special Meeting”).

Aditxt, Inc. (NASDAQADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today shared an important milestone for its target acquisition, Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (“Appili”), announcing that the U.S. Food and Drug Administration (“FDA”) has provided positive feedback regarding the development strategy for ATI-1801. For additional information, please visit https://finance.yahoo.com/quote/APLIF/news/.

Aditxt, Inc. (NASDAQADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today announced the hosting of an update and Q&A session with CEO Amro Albanna this Friday, November 1, 2024, at 11:30 AM ET. This update aims to connect with our stakeholders, including investors and the public, offering insights into the Company’s latest developments and will address pre-submitted questions.

Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQADTX), a social innovation platform dedicated to accelerating promising health innovations, today announced the appointment of Sylvia Hermina to its Board of Directors. With over 20 years of experience advising public companies on corporate governance, mergers and acquisitions, and shareholder relations, Ms. Hermina brings a wealth of expertise in fostering effective and impactful engagement between management teams and stakeholders.

Aditxt, Inc. (NASDAQADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today announced the achievement of a key milestone under the Amended and Restated Merger Agreement, as amended (the “A&R Merger Agreement”) toward completion of its intended acquisition of women’s health innovator Evofem Biosciences, Inc. (“Evofem”) (OTCQB: EVFM).

Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQADTX), a social innovation platform dedicated to accelerating promising health innovations, today announced a virtual fireside chat set for October 28, 2024, at 11:30 AM Eastern Time. The event will be hosted by Amro Albanna, Co-Founder and CEO of Aditxt, featuring Saundra Pelletier, CEO of Evofem Biosciences, Inc. (“Evofem”) (OTCQB: EVFM), and will be moderated by renowned physician and television personality Dr. Drew Pinsky.

Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQADTX), an innovation platform dedicated to accelerating promising health innovations with two existing programs focused on immune health and precision health, announced that Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (“Appili”) has commenced the mailing of its management information circular in connection with the upcoming special meeting of their shareholders, which will be held virtually on November 6, 2024. Appili’s board of directors has recommended the shareholders’ vote in favor of the proposed acquisition by Aditxt.

Aditxt, Inc. (“Aditxt” “Company”) (NASDAQADTX), an innovation platform dedicated to accelerating promising health innovations, today announced the hosting of an update and Q&A session with CEO Amro Albanna this Friday, October 11, 2024, at 11:30 AM EDT. This update aims to connect with our stakeholders, including investors and the public, offering insights into the Company’s latest developments and will address pre-submitted questions.

Aditxt, Inc. (“Aditxt” ) (NASDAQADTX), an innovation platform dedicated to accelerating promising health innovations, and Evofem Biosciences, Inc. (“Evofem”) (OTCQB: EVFM), a pioneer in women's health, today announced the completion of the Third Parent Equity Investment under the Amended and Restated Merger Agreement, as amended (the “Agreement”). This investment further strengthens the strategic and collaborative relationship between the two companies as they jointly seek to expand access to healthcare solutions for women globally.

Aditxt, Inc. (NASDAQADTX) (“Aditxt” or the “Company”), an innovation platform dedicated to accelerating promising health innovations, today provided an update on its plans for 2024 year-end.

Aditxt, Inc. (NASDAQADTX) (“Aditxt” or the “Company”), an innovation platform dedicated to accelerating promising health innovations, announced today that it will effect a 1-for-40 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market on October 2, 2024, the Company’s common stock will trade on a post-split basis under the same symbol ADTX. The reverse stock split was approved by the Company’s stockholders at the annual meeting held on August 7, 2024, with the final ratio determined by the Company’s board of directors.

Aditxt, Inc. (NASDAQADTX) (“Aditxt” or the “Company”), an innovation platform dedicated to accelerating promising health innovations, today announced that its acquisition target, Evofem Biosciences, Inc. (“Evofem”) (OTCQB: EVFM), today filed a preliminary proxy to seek stockholder approval of transactions contemplated under the Amended and Restated Merger Agreement dated as of July 12, 2024 (the “Merger Agreement”), with Aditxt and Adifem, Inc., a wholly-owned subsidiary of Aditxt (“Adifem”), pursuant to which, and on the terms and subject to the conditions thereof, Adifem will merge with and into Evofem, with Evofem surviving as a wholly owned subsidiary of Aditxt.

Aditxt, Inc. (NASDAQADTX) (“Aditxt” or the “Company”), an innovation platform dedicated to accelerating promising health innovations, today announced that its majority-owned subsidiary, Pearsanta, Inc. (“Pearsanta”), has entered into a Market Development Collaboration Agreement (the “Agreement”) with women’s health pioneer Evofem Biosciences, Inc. (“Evofem”) (OTCQB: EVFM) focused on Pearsanta’s blood-based diagnostic test for endometriosis.

Aditxt, Inc. (NASDAQADTX) (“Aditxt” or the “Company”), an innovation platform dedicated to accelerating health innovations, and women’s health pioneer, Evofem Biosciences, Inc. (OTCQB: EVFM) (“Evofem”) today announced they have entered into the Second Amendment to the Amended and Restated Agreement and Plan of Merger (the “Second Amendment”), under which Aditxt intends to acquire Evofem.

Aditxt, Inc. ("Aditxt") (NASDAQADTX), a company dedicated to discovering, developing, and deploying promising health innovations, announced that its subsidiary, Pearsanta, Inc. (“Pearsanta”), has submitted a grant application to the Prostate Cancer Research Program (PCRP) under the Department of Defense (DoD) Implementation Science Award funding mechanism seeking $2 million in funding. This non-dilutive funding initiative aims to advance the early detection and management of prostate cancer, a disease that remains one of the most prevalent and challenging cancers affecting men globally.

Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQADTX), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today announced that it will present virtually and participate in one-on-one investor meetings at the H.C. Wainwright 26th Annual Global Investment Conference, taking place at the Lotte New York Palace Hotel in New York City from September 9th-11th, 2024.

Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQADTX), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today announced that its subsidiary, Pearsanta, Inc. (“Pearsanta”), appointed Christoper Mitton as President.

Aditxt, Inc. (“Aditxt” or “the Company”) (NASDAQADTX), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today announced that it had entered into a third amending agreement with Appili Therapeutics, Inc. (TSX: APLI; OTCPink: APLIF) (“Appili”), a biopharmaceutical company focused on developing innovative treatments and vaccines to combat some of the most challenging infectious diseases and potential bioterrorism threats.

Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQADTX), an innovation platform dedicated to discovering, developing, and deploying promising innovations, announced the successful passage of all proposals at its recent annual shareholders' meeting.

Aditxt, Inc., (NASDAQADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced the closing of a previously announced registered direct offering price at-the-market under Nasdaq rules for the purchase and sale of an aggregate of 1,130,189 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $1.06 per share (or common stock equivalents in lieu thereof).

Aditxt, Inc., (NASDAQADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that it has entered into a securities purchase agreement with certain institutional investors for the purchase and sale of an aggregate of 1,130,189 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $1.06 per share (or common stock equivalents in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. The offering is expected to close on or about August 9, 2024, subject to the satisfaction of customary closing conditions.

Aditxt, Inc. ("Aditxt") (NASDAQADTX), a company dedicated to discovering, developing, and deploying promising health innovations, announced that its subsidiary, Pearsanta, Inc. (“Pearsanta”) has submitted a proposal for the Clinical Trial Translational Endpoints Research Award to the Congressionally Directed Medical Research Programs (CDMRP) of the Department of Defense. The proposal aims to validate a novel assay based on Pearsanta’s proprietary Mitomic® Technology for the early detection of ovarian cancer.

Aditxt, Inc. (“Aditxt”) (NASDAQADTX), a company dedicated to discovering, developing, and deploying promising health innovations, and its wholly-owned subsidiary, Adivir, Inc., have entered into a second Amending Agreement (the “Amending Agreement”) with Appili Therapeutics Inc. (“Appili”) (TSX: APLI; OTCPink: APLIF), a biopharmaceutical company developing treatments and vaccines for infectious diseases and medical countermeasures. Under the Amending Agreement, (a) the Outside Date (as defined in the Arrangement Agreement) was changed from August 30, 2024 to September 30, 2024, (b) the deadline to convene Appili’s special shareholders’ meeting was changed from August 30, 2024, to September 30, 2024, and (c) the deadline for Aditxt to complete the Financing (as defined below) was changed from August 30, 2024 to September 15, 2024, or such later date as the parties may agree in writing. Aditxt will acquire all issued and outstanding Class A common shares of Appili through a court-approved plan of arrangement governed by the Canada Business Corporations Act. The transaction is targeted for closure by September 30, 2024.

Aditxt, Inc. (“Aditxt”) (NASDAQADTX), a company dedicated to discovering, developing, and deploying promising health innovations, announces this past Friday, July 12th, Aditxt, its wholly owned subsidiary Adifem, Inc., and Evofem Biosciences, Inc.’s (“Evofem”) (OTCQB: EVFM) amended and restated their Merger Agreement. This amended and restated Merger Agreement, among others, addresses pre-closing issues critical for Evofem’s future success, including interim financing needs. The other revisions to the Merger Agreement, alongside additional interim financing for Evofem, include substituting cash for Aditxt’s common stock as the consideration for Evofem’s common stock in the merger and additional changes relating to it. Aditxt and Evofem are diligently working to close the contemplated transaction in the second half of 2024.

In the first and second paragraphs, shares of common stock should read: 1.6 million, (instead of 1.65 million). Second paragraph, second sentence, the conversion price of the Series C-1 Convertible Preferred Stock should read: $2.595 per share (instead of $2.47 per share). In the second paragraph, fourth sentence, the warrant exercise price should read: $2.47 (instead of $2.595 per share).

Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQADTX), a company dedicated to discovering, developing, and deploying promising health innovations, today announced that it has entered into a definitive arrangement agreement ("Arrangement Agreement") to acquire Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (“Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. Under the Arrangement Agreement, Aditxt’s wholly owned subsidiary, Adivir, Inc. (“Adivir”) agreed to acquire all issued and outstanding Class A common shares of Appili (the “Appili Shares”) through a court-approved plan of arrangement under the Canada Business Corporations Act ("Transaction").

Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQADTX), a company dedicated to discovering, developing, and deploying promising health innovations, today announced the acquisition of a portfolio of EEG brain monitoring technologies and devices formerly owned by Brain Scientific, Inc. (“Brain Scientific”). The products targeting the neurology monitoring market will be essential in shaping its dynamic landscape for neurological care.

Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQADTX), a company dedicated to discovering, developing, and deploying promising health innovations, today announces that the Company and its subsidiary, Pearsanta, Inc. (“Pearsanta”), has acquired MDNA Life Sciences Inc.’s (“MDNA”) proprietary, early disease and cancer detection platform. This strategic move reinforces Pearsanta’s dedication to enhancing patient outcomes through early disease detection and the power of precision diagnostics. The portfolio of assets to be acquired includes the pioneering Mitomic™ technology that harnesses the unique attributes of Mitochondrial DNA (“mtDNA”) to detect diseases at their earliest stages with precision and minimal invasiveness.

Aditxt, Inc. (NASDAQADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that it has closed its previously announced private placement for the purchase and sale of an aggregate of 1,237,114 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $4.85 per share (or pre-funded warrants in lieu thereof) and accompanying warrants, priced at-the-market under Nasdaq rules. Each share of common stock (or pre-funded warrant in lieu thereof) is being offered in the offering together with warrants to purchase two share of common stock at an exercise price of $4.60 per share. The warrants will be exercisable immediately upon issuance and expire three years from the date of issuance.

Aditxt, Inc. (“Aditxt” or “the Company”) (NASDAQADTX), a company dedicated to discovering, developing, and deploying promising health innovations, today announced that it has received confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) Hearing Panel that it has regained compliance with minimum stockholders’ equity requirement in Nasdaq Listing Rule 5550(b)(1), subject to a mandatory panel monitor until December 29, 2024.

Aditxt, Inc., (NASDAQADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,237,114 shares of common stock (or pre-funded warrant in lieu thereof) at a purchase price of $4.85 per share (or pre-funded warrant in lieu thereof) and accompanying warrant, in a private placement priced at-the-market under Nasdaq rules. Each share of common stock (or pre-funded warrant in lieu thereof) is being offered in the offering together with warrants to purchase two shares of common stock at an exercise price of $4.60 per share. The warrants will be exercisable immediately upon issuance and expire three years from the date of issuance. The private placement is expected to close on or about January 3, 2024, subject to the satisfaction of customary closing conditions.

Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQADTX), a company dedicated to discovering, developing, and deploying promising health innovations, and Evofem Biosciences, Inc. (“Evofem”) (OTCQB: EVFM), a pioneer in women’s health, today announced the signing of a definitive agreement (the “Agreement”) under which Aditxt is to acquire Evofem in consideration of the issuance of a combination of common stock and preferred stock, and the assumption of certain senior indebtedness, having an aggregate amount of approximately $100 million (the “Transaction”). Pending a successful Transaction, it will also mark the establishment of a women's health mission within Aditxt's platform, aligning with global healthcare needs.

Chief Executive Officer, Amro Albanna to Present at 9:00am Eastern Time on Thursday, October 12, 2023

Aditxt, Inc., (NASDAQADTX) (“Aditxt” or the “Company”), a global innovation activation company focused on the discovery, development, and deployment of technologies that monitor and modulate the immune system, announced today that it has appointed Ernie Lee to serve as the Chief Executive Officer of the Company’s wholly-owned subsidiary Pearsanta, Inc. (“Pearsanta”). Ernie’s appointment is intended to accelerate the commercial launch of Test2Treat.me. Test2Treat.me is an end-to-end, business-to-business (“B2B”) and direct-to-consumer (“DTC”) clinical diagnostic testing services platform for retail pharmacies, physician practices, employee benefit programs, and consumers.

Aditxt,® Inc, (NASDAQADTX) (“Aditxt” or the “Company”), a global innovation company focused on developing and commercializing technologies that monitor and modulate the immune system, today announced that the Aditxt management team will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11th -13th, 2023, in New York City. The in-person venue for the event is the Lotte New York Palace Hotel in New York City located at 455 Madison Avenue. Virtual participation will be staged simultaneously with over 550 company presentations scheduled as live feeds or available on-demand.

Aditxt, Inc., (NASDAQADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that it has closed its previously announced private placement for the purchase and sale of an aggregate of 1,000,000 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $10.00 per share (or pre-funded warrants in lieu thereof) and accompanying warrant, priced at-the-market under Nasdaq rules. Each share of common stock (or pre-funded warrant in lieu thereof) is being offered in the offering together with warrants to purchase one share of common stock at an exercise price of $10.00 per share. The warrants will be exercisable immediately upon issuance and expire five and one-half years from the date of issuance.

Aditxt, Inc. (NASDAQADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,000,000 shares of common stock (or pre-funded warrant in lieu thereof) at a purchase price of $10.00 per share (or pre-funded warrant in lieu thereof) and accompanying warrant, in a private placement priced at-the-market under Nasdaq rules. Each share of common stock (or pre-funded warrant in lieu thereof) is being offered in the offering together with warrants to purchase one share of common stock at an exercise price of $10.00 per share. The warrants will be exercisable immediately upon issuance and expire five and one-half years from the date of issuance. The private placement is expected to close on or about September 5, 2023, subject to the satisfaction of customary closing conditions.

Aditxt®, Inc. (NASDAQADTX) (“Aditxt” or the “Company”), a global innovation company focused on innovation and activation of precision medicine therapeutics and technologies that monitor and modulate the immune system, is pleased to provide an important update regarding its innovation programs and strategic M&A initiatives.

First paragraph, first sentence of release should read: Aditxt, Inc. (NASDAQADTX) (“Aditxt or the “Company”), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, announced today that it will effect a 1-for-40 reverse split of its common stock (instead of Aditxt, Inc. NASDAQ: ADTXNASDAQADTX)

Aditxt,® Inc. (NASDAQADTX) (“Aditxt” or the “Company”), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, is pleased to announce the signing of an exclusive non-binding Letter of Intent (“LOI”) by Pearsanta,™ Inc. (“Pearsanta”), a wholly-owned subsidiary of Aditxt, to acquire both Natural State Laboratories, LLC (“NSL”) and Natural State Genomics, LLC (“NSG”) (collectively, “Natural State Entities” or “NSL/NSG”). The Natural State Entities are a premier full-service laboratory headquartered in Little Rock, Arkansas, offering diagnostic, molecular, genetic, and toxicology services.

Aditxt®, Inc. (NASDAQADTX) (“Aditxt” or the “Company”), a global innovation company focused on therapeutics and technologies that modulate and monitor the immune system, today announces that its subsidiary Adimune™, Inc. (“Adimune”), has signed a clinical trial agreement with Mayo Clinic to advance clinical studies targeting autoimmune diseases of the central nervous system (“CNS”) with the initial focus on the rare, but debilitating, autoimmune disease Stiff Person Syndrome (“SPS”). Adimune was founded earlier this year to lead Aditxt’s immune modulation therapeutic programs.

Aditxt, Inc. (NASDAQADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of an aggregate of 1,585,350 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $1.22 per share (or common stock equivalents in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered warrants to purchase up to 3,170,700 shares of common stock with an exercise price of $0.86 per share which will be immediately exercisable for a period of three years following issuance. The offering is expected to close on or about April 24, 2023, subject to the satisfaction of customary closing conditions.

Aditxt,® Inc. (NASDAQADTX) (“Aditxt” or the “Company”), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, is pleased to announce the signing of an asset purchase agreement with Cellvera, Ltd. (”Cellvera”) that grants Aditxt (whether directly or in its recently formed wholly owned subsidiary Adivir, ™ Inc. (“Adivir”), a 50% ownership in G Response Aid FZE (“GRA” or “Global Response Aid”) with the other 50% owned by global logistics leader Agility, Inc. (KW: AGLTY) (“Agility”). The consideration for the transaction is (A) $24.5 million, comprised of: (i) the forgiveness of Aditxt’s $14.5 million loan to Cellvera, and (ii) $10 million in cash, and (B) future royalties for 7 years. Together with Dr. Reddy’s Laboratories, Ltd. NYSE: RDYNYSERDY)

Aditxt,® Inc, (NASDAQADTX) (“Aditxt” or the “Company”), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, is pleased to provide an important update regarding its three innovation programs and strategic M&A initiatives.

Aditxt, Inc., (NASDAQADTX) (“Aditxt” or the “Company”), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, is pleased to announce Maureen Connolly has joined Aditxt as Chief Content and Engagement Officer. Connolly is an award-winning content strategist and audience builder with 25+ years of experience in the health, science, wellness, technology, and chronic conditions space. She works with product, marketing, and engineering teams to create content platforms where businesses can engage with global audiences while building communities that feel supported and connected.

Aditxt, Inc., (NASDAQADTX) (“Aditxt” or the “Company”), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces it has retained Riverside Management Group, LLC (“Riverside Management Group” or “RMG”), a merchant banking firm providing investment banking advisory services, to support the Company’s ongoing growth and revenue generating plans for its subsidiary Pearsanta, Inc. (“Pearsanta”) and other Aditxt programs.

Aditxt, Inc., (NASDAQADTX) (“Aditxt” or the “Company”), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces the formation of a U.S.-based wholly- owned subsidiary, Pearsanta, Inc. (“Pearsanta”), to accelerate the growth of Aditxt’s second program, AditxtScore™, through future strategic revenue and growth-oriented transactions.

Aditxt, Inc. (NASDAQADTX) (“Aditxt” or the “Company”), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces the formation of a U.S.-based subsidiary Adimune, Inc. (“Adimune™) and its plans towards submission of a Clinical Trial Application (“CTA”) for its immunotherapeutic technology drug candidate, ADI™-100 (“ADI™-100” or “ADI™”). The CTA application will request approval for Adimune™ to conduct the first-in-human study in psoriasis patients, beginning in the second half of 2023. A second study is also planned for type 1 diabetes.

Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces that its program Adimune™ has initiated the GMP manufacturing of drug candidate ADI™-100 as a key milestone toward its goal to begin first-in-human trials during the second half of 2023. Pending regulatory approvals, these trials will be performed in autoimmune diseases, with psoriasis as the first indication to be studied. Adimune’s™ nucleic acid-based technology, called Apoptotic DNA Immunotherapy™ (“ADI™”), restores/induces immune tolerance in an antigen-specific way, and is based on a unique mechanism of action with a potentially profound efficacy benefit without immune suppression. Encouraging toxicology study results for ADI™-100 earlier established the safety profile of the drug candidate in the treatment of autoimmune diseases.

Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces publication of a mathematical model for predicting the durability and rate of decay of neutralizing antibodies to SARS-CoV-2 in a peer-reviewed research paper in the Journal of Theoretical Biology.

Aditxt, Inc.’s (NASDAQADTX) (“Aditxt”, or the “Company”) AditxtScore™ is featured by FedEx in a video presentation that showcases the various ways in which both companies are playing critical roles in a challenging environment that includes the nation’s response to COVID-19.

Aditxt, Inc. (NASDAQADTX) (“Aditxt” or the “Company”), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces it has received confirmation from The Nasdaq Stock Market LLC Hearing Panel (“Nasdaq”) that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2), meets the stockholders’ equity requirement in Nasdaq Listing Rule 5550(b)(1) and meets all other applicable criteria for continued listing.

Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system, today provides shareholders with a corporate update following the completion of a reverse stock split and closing of a previously announced $20 million public offering.

Aditxt, Inc., (Nasdaq: ADTX) (the “Company” or “Aditxt”), a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system, today announced the closing of its previously announced public offering of 3,333,333 shares of its common stock (or common stock equivalents in lieu thereof), together with warrants to purchase up to 3,333,333 shares of its common stock at a combined offering price to the public of $6.00 per share (or common stock equivalent) and associated warrant. The warrants have an exercise price of $6.00 per share, are exercisable immediately upon issuance, and will expire five years following the date of issuance.

Aditxt, Inc. (Nasdaq: ADTX), a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system, announced today that it will effect a 1-for-50 reverse split of its common stock effective as of 4:01 p.m. Eastern Time on September 13, 2022. Commencing with the opening of trading on The Nasdaq Capital Market on September 14, 2022, the Company’s common stock will trade on a post-split basis under the same symbol ADTX. The reverse stock split was approved by the Company’s stockholders at the special meeting held on September 7, 2022, with the final ratio determined by the Company’s board of directors.

Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the "Company"), a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system, today announces that its therapeutic program Adimune™, has successfully completed a toxicology study that indicates the safety profile of ADI™-100, the Company’s immunotherapeutic technology drug that addresses rejection of transplanted organs, skin allografting, autoimmune diseases and allergies.

Aditxt, Inc. (“Aditxt”, or the “Company”) (Nasdaq: ADTX), a biotech innovation company developing technologies focused on mapping and reprogramming the immune system, today is announcing a multiyear partnership with GRS, an affiliate of marketing powerhouse Guthy-Renker, LLC (“Guthy-Renker”). This partnership will focus on building awareness and visibility among consumers and healthcare providers for the AditxtScore™ Immune Monitoring Platform. Aditxt plans to work with GRS to produce and subsequently air AditxtScore™ TV commercials in order to help set the stage for an intended AditxtScore™ rollout to medical offices, pharmacies, laboratories, and employers nationwide.

Aditxt, Inc. (“Aditxt”, or the “Company”) (Nasdaq: ADTX) has entered into a revenue-sharing agreement with Cellvera, and certain of its affiliates. The agreement is designed to drive strategic revenue and growth starting in 2022 and provide enhanced security for the Company’s $14.5 million loan, plus interest to Cellvera Global Holdings LLC (“Cellvera”), formerly AiPharma Global Holdings LLC. The Company has signed the agreement as consideration for Aditxt’s separate agreement to extend the term of the previously announced loan and forbearance agreements. Cellvera holds exclusive worldwide rights (except Japan) to a broad spectrum oral antiviral drug targeting COVID-19 and 11 other infectious diseases. Cellvera is focused on discovering, developing, and commercializing antimicrobial therapies across a broad spectrum of infectious diseases, including COVID-19.

Aditxt, Inc. (Nasdaq: ADTX), a biotech innovation company developing technologies focused on mapping and reprogramming the immune system, announced today that Company CEO & Co-Founder, Amro Albanna, has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT.

Aditxt, Inc. (“Aditxt,” or the “Company”) (Nasdaq: ADTX), a biotech innovation company with a mission to advance humanity’s transition to the “Age of Immunity,” has submitted two EUA applications for AditxtScore™ for COVID-19. This lab-developed blood test provides a more comprehensive profile of the body’s immune response to COVID-19.

Aditxt, Inc. (“Aditxt” or the “Company”) (Nasdaq: ADTX) announced today it is participating in Edison Group’s Open House Event, scheduled to take place virtually this month.

Aditxt, Inc. (“Aditxt” or the “Company”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced it will host an online business update townhall meeting with Amro Albanna, Co-Founder & CEO on Tuesday, January 18th from 2:00 to 3:00 pm ET.

Aditxt, Inc. (“Aditxt” or the “Company”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced it had signed an amendment to its February 3, 2020, Exclusive License Agreement with Stanford University, extending Aditxt’s exclusive right to license the technology deployed in AditxtScore™ and securing worldwide exclusivity in all fields of use of the licensed technology (the “Technology”).

Aditxt, Inc. (“Aditxt” or the “Company”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced it had signed a non-binding letter of intent (“LOI”) to acquire a company focused on developing Point-of-Care diagnostics for early detection of diseases including cancers and SARS-CoV-2 (COVID-19) through a range of non-invasive and affordable point of care and at-home/in-office test kits.

Aditxt, Inc. (“Aditxt”, or the “Company”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, announced today the closing of its previously announced underwritten public offering of 16,575,000 units, consisting of shares of its common stock and warrants to purchase up to 16,575,000 shares of its common stock at a public offering price of $1.05 per unit, for aggregate gross proceeds of $17,403,750, prior to deducting underwriter discounts, commissions, and other offering expenses. Units were not issued or certificated. The shares of common stock and warrants were issued separately. The warrants permit the holder to purchase one share of common stock at an exercise price of $1.15 per share and expire five years after the date of issuance. The underwriter has a 45-day option to purchase up to 2,486,250 additional shares of common stock and/or warrants to purchase up to an aggregate of 2,486,250 shares of common stock, on one or more occasions and in any combinations thereof, from us at the public offering price, less the underwriting discounts and commissions. The underwriter exercised the over-allotment option with respect to the warrants to purchase up to an aggregate of 2,486,250 shares of common stock, which exercise also has closed. The underwriter continues to hold a 45-day option to purchase up to 2,486,250 additional shares of common stock.

Aditxt, Inc. (“Aditxt” or the “Company”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, announced today that it has entered into an amendment to its previously announced transaction agreement with AiPharma Global extending the outside date by which the parties have to execute a definitive agreement from November 30, 2021 to December 16, 2021, and to remove the $4 million termination fee from the transaction agreement and associated credit agreement. In addition, the parties agreed to reduce AiPharma Global’s borrowing capacity under the credit agreement from $8.5 million to $8 million and to require an aggregate cash payment of $500,000 to be made in one or more payments at the initial closing and/or secondary closing, as mutually agreed by the parties.

Aditxt, Inc. (“Aditxt”, or the “Company”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, announced today the pricing of an underwritten public offering of 16,575,000 units, consisting of shares of its common stock (or pre-funded warrants to purchase common stock) and warrants to purchase up to 16,575,000 shares of its common stock at a public offering price of $1.05 per unit, for aggregate gross proceeds of $17,403,750, prior to deducting underwriter discounts, commissions, and other offering expenses. Units will not be issued or certificated. The shares of common stock and warrants are immediately separable and will be issued separately. The warrants permit the holder to purchase one share of common stock at an exercise price of $1.15 per share and expire five years after the date of issuance. In addition, the Company has granted the underwriter a 45-day option to purchase up to 2,486,250 additional shares of common stock and/or warrants to purchase up to an aggregate of 2,486,250 shares of common stock, on one or more occasions and in any combinations thereof, from us at the public offering price, less the underwriting discounts and commissions. The offering, which was led by a leading healthcare investor, is expected to close on December 3, 2021, subject to customary closing conditions.

Aditxt, Inc. (“Aditxt”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, announced today the launch of an underwritten public offering.

Aditxt, Inc. (“Aditxt” or the “Company”) (Nasdaq: ADTX), a biotech innovation company that improves the health of the immune system, announced today that the Johnson County Sherriff’s Office, the largest law enforcement agency in the State of Kansas with over 700 employees, will become the first agency in the Nation to deploy AditxtScore™ for assessing the immune status for COVID-19 in its employees.

Aditxt, Inc. (“Aditxt”) (Nasdaq: ADTX), has announced a webinar at 2pm ET this afternoon to discuss its earlier announcement today.

Aditxt, Inc. (“Aditxt”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced that the global Phase 3 PRESECO (PREventing SEvere COVID-19) trial evaluating oral Avigan®/Reeqonus™ (favipiravir) as a potential at-home therapy for patients with mild-to-moderate COVID-19, which was being run by Appili Therapeutics, Inc. (“Appili”)(TSX: APLI), a consortium partner of AiPharma Global Holdings LLC (“AiPharma Global”), did not achieve statistical significance on the primary endpoint of time to sustained clinical recovery. Additional analyses of the trial data are ongoing.